Innovative albumin-based material produced using a non-denaturing process to preserve the structure of the protein and allow the loading of sensitive chemical/biological molecules. Albumin is a natural drug carrier with low immunogenicity: good candidate for easily functionalisable biomaterials. Targeted applications: Implantable Medical Device for human/veterinary controlled release of drugs.

Medical needles are used in mini-invasive percutaneous procedures and are deep-tissue inserted. ARC technology adds a mechanical option to medical needles allowing the correction of its trajectory and thus better reach the targeted tissue. Its main applications are biopsy and cancerous lesion treatment.

ATK develops a NCE with selective positive modulation of TrkB activation by BDNF (PAM). Neuroprotection potential for various neurodegenerative diseases as Alzheimer’s, Parkinson’s, or Huntington diseases. Small molecule crossing blood-brain barrier with high TrkB affinity and selectivity.
In vivo PoC in Huntington Disease.

New-infrared coating and implantable materials used as medical biosensors. Targeted applications for this new functionalized biomaterial: diagnostic detection for inflammatory and infectious processes, monitoring of patients suffering from chronic inflammatory diseases, monitoring of patients during or after surgical interventions

Small molecule (NCE) agonist of sigma1 receptor for the treatment of several neurodegenerative diseases. 2 chemical series, protected by 2 patents, highly selective and affine. Preliminary in-vivo data available on Alzheimer's, ALS (amyotrophic lateral sclerosis) and CIAS (cognitive impairement associated with schizophrenia) models.

Dermapol is an innovative tool which helps skin pathologies diagnosis, such as melanoma. Detecting a polarimetric signature of pathologic tissues, it brings a considerable and objective help to practitioners. Dermapol device is portable and miniaturised. Currently under clinical study.

This project aims at increasing the therapeutic window of ADCs by developing a linker that releases the payload selectively in cancerous cells.
Using cytometric screening technology, we identified a new linker with unprecedented selectivity for cancer cells which express specific enzymes.

Restoring apelin signaling in sarcopenia considerably enhanced muscles’ function and regenerative capacity. GlucoFAP13 project proposes apelin-13 derivatives stabilized by an innovative technology. Evaluation ongoing for efficacy in improving muscle strength, stamina and endurance in a sarcopenic mouse model.

News targets and gene therapy approaches to treat centronuclear myopathies. 2 proteins identified as relevant targets for the different forms of centronuclear myopathies (XL-CNM and AD-CNM). We propose a patents portfolio covering these targets for CNM treatment, based on solid and published proof of concept.

New antibody fragments for the treatment of thrombosis (stroke, thrombotic purpura, coronary syndrome...). Our approach is directed against a platelet receptor that is not currently targeted by commercially available products, and prevents thrombus formation with a reduced bleeding risk.